论文部分内容阅读
应用吡柔比星(Thp,深圳万乐药业有限公司产品)联合化疗方案治疗初治高危、复发难治性急性白血病共111例,现将结果报告如下。病例和方法1 研究对象所有病例均符合文献[1]的诊断标准。2002年1月至2004年6月,在多中心共入组患者111例,男61例,女50例,中位年龄32(12～71)岁,其中初治高危组47例[急性非淋巴细胞白血病(ANLL)26例,急性淋巴细胞白血病(ALL)15例,混合细胞白血病6例],复发难治组分别有
The application of pirarubicin (Thp, Shenzhen Wan Le Pharmaceutical Co., Ltd.) combined with chemotherapy in the treatment of newly diagnosed high-risk, relapsed and refractory acute leukemia in a total of 111 cases, the results reported below. Cases and methods 1 All subjects in accordance with the diagnostic criteria of the literature [1]. From January 2002 to June 2004, 111 patients were enrolled in the multicentre group, including 61 males and 50 females, with a median age of 32 (ranged from 12 to 71) years. Among them, 47 were newly diagnosed as high risk group [acute non-lymph 26 cases of cell leukemia (ANLL), 15 cases of acute lymphoblastic leukemia (ALL), 6 cases of mixed cell leukemia], refractory refractory group were